Inhibition of p38 MAPK attenuates renal atrophy and fibrosis in a murine renal artery stenosis model

Abstract

Renal artery stenosis (RAS) is an important cause of chronic renal dysfunction. Recent studies have underscored a critical role for CCL2 (MCP-1)-mediated inflammation in the progression of chronic renal damage in RAS and other chronic renal diseases. In vitro studies have implicated p38 MAPK as a critical intermediate for the production of CCL2. However, a potential role of p38 signaling in the development and progression of chronic renal disease in RAS has not been previously defined. We sought to test the hypothesis that inhibition of p38 MAPK ameliorates chronic renal injury in mice with RAS. We established a murine RAS model by placing a cuff on the right renal artery and treated mice with the p38 inhibitor SB203580 or vehicle for 2 wk. In mice treated with vehicle, the cuffed kidney developed interstitial fibrosis, tubular atrophy, and interstitial inflammation. In mice treated with SB203580, the RAS-induced renal atrophy was reduced (70% vs. 39%, P < 0.05). SB203580 also reduced interstitial inflammation and extracellular matrix deposition but had no effect on the development of hypertension. SB203580 partially blocked the induction of CCL2, CCL7 (MCP-3), CC chemokine receptor 2 (CCR2), and collagen 4 mRNA expression in the cuffed kidneys. In vitro, blockade of p38 hindered both TNF-α and TGF-β-induced CCL2 upregulation. Based on these observations, we conclude that p38 MAPK plays a critical role in the induction of CCL2/CCL7/CCR2 system and the development of interstitial inflammation in RAS.

Epigallocatechin-3-gallate reduces tubular cell apoptosis in mice with ureteral obstruction

“…MAPK signaling pathway is a classical signaling pathway, which can be activated by various factors including TGF-b1 [37]. Studies demonstrate that MAPK signaling pathway regulates cell apoptosis and is involved in tubular injury, and MAPK signaling inhibition can prevent apoptosis of tubular cells [18,38]. EGCG is reported to modulate MAPK signaling in various types of cells.…”

Astragaloside IV Ameliorates Renal Fibrosis via the Inhibition of Mitogen-Activated Protein Kinases and Antiapoptosis In Vivo and In Vitro

“…The MAPK pathway is a classic signaling pathway that regulates cell apoptosis and inflammation and is involved in serious tubular injury (Qin et al, 2012;Zheng et al, 2012;Wang et al, 2013). Qin et al (2012) reported that A. membranaceus, from which AS-IV is purified, inhibited the phospho-p38 MAPK pathway in advanced glycation endproduct-stimulated macrophages.…”

Danshensu Inhibits β-Adrenergic Receptors-Mediated Cardiac Fibrosis by ROS/p38 MAPK Axis

“…29) Inhibition of p38 MAPK can attenuate renal and lung fibrosis. 23,30,31) In addition, p38 MAPK plays an important role in CF proliferation. 32,33) In this study, CFs showed a significant increase in p38 phosphorylation when treated with ISO, as compared with untreated controls.…”